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Abstract
Background: HIV-2 is endemic in West Africa and has spread throughout Europe. However, the alternatives for
HIV-2-infected patients are more limited than for HIV-1. Raltegravir, an integrase inhibitor, is active against wild-type
HIV-2, with a susceptibility to this drug similar to that of HIV-1, and is therefore a promising option for use in the
treatment of HIV-2-infected patients. Recent studies have shown that HIV-2 resistance to raltegravir involves one of
three resistance mutations, N155H, Q148R/H and Y143C, previously identified as resistance determinants in the HIV-
1 integrase coding sequence. The resistance of HIV-1 IN has been confirmed in vitro for mutated enzymes
harboring these mutations, but no such confirmation has yet been obtained for HIV-2.
Results: The integrase coding sequence was amplified from plasma samples collected from ten patients infected
with HIV-2 viruses, of whom three RAL-naïve and seven on RAL-based treatment at the time of virological failure.
The genomes of the resistant strains were cloned and three patterns involving N155H, G140S/Q148R or Y143C
mutations were identified. Study of the susceptibility of integrases, either amplified from clinical isolates or
obtained by mutagenesis demonstrated that mutations at positions 155 and 148 render the integrase resistant to
RAL. The G140S mutation conferred little resistance, but compensated for the catalytic defect due to the Q148R
mutation. Conversely, Y143C alone did not confer resistance to RAL unless E92Q is also present. Furthermore, the
introduction of the Y143C mutation into the N155H resistant background decreased the resistance level of
enzymes containing the N155H mutation.
Conclusion: This study confirms that HIV-2 resistance to RAL is due to the N155H, G140S/Q148R or E92Q/Y143C
mutations. The N155H and G140S/Q148R mutations make similar contributions to resistance in both HIV-1 and HIV-
2, but Y143C is not sufficient to account for the resistance of HIV-2 genomes harboring this mutation. For Y143C to
confer resistance in vitro, it must be accompanied by E92Q, which therefore plays a more important role in the
HIV-2 context than in the HIV-1 context. Finally, the Y143C mutation counteracts the resistance conferred by the
N155H mutation, probably accounting for the lack of detection of these mutations together in a single genome.
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Background
HIV-2 is endemic in West Africa and has spread
throughout Europe over the last two decades [1,2]. The
development of seven different classes of antiretroviral
drugs has led to the establishment of highly active treat-
ments that have had a profound effect on the morbidity
and mortality of HIV-1-infected individuals. These
classes are nucleoside (NRTIs), nucleotide (NtRTIs) and
non nucleoside (NNRTIs) reverse transcriptase inhibi-
t o r s ,p r o t e a s ei n h i b i t o r s( P I s ) ,e n t r yi n h i b i t o r s ,f u s i o n
inhibitors and integrase (IN) inhibitors (INIs). Despite
this apparent diversity, the alternatives for HIV-2-
infected patients are more limited because NNRTIs and
fusion inhibitors are not active against HIV-2 [3,4] and
HIV-2 is also less sensitive to some PIs [5-7]. It has also
* Correspondence: mouscadet@lbpa.ens-cachan.fr
1LBPA, CNRS, Ecole Normale Supérieure de Cachan, Cachan, France
Full list of author information is available at the end of the article
Ni et al. Retrovirology 2011, 8:68
http://www.retrovirology.com/content/8/1/68
© 2011 Ni et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.been suggested that the genetic barrier is weaker in
HIV-2, potentially resulting in the more rapid emer-
gence of resistance to other PIs [8,9]. The development
of novel treatments based on drug classes highly effec-
tive against HIV-2 is therefore essential. INIs are active
against HIV-2 IN and are therefore a promising option
for use in the treatment of HIV-2-infected patients
[10,11]. IN plays a key role in the viral replication cycle.
This makes it an attractive target for antiretroviral ther-
apy, together with two other enzymes: reverse transcrip-
tase (RT) and protease (P). The viral integrase catalyzes
two spatially and temporally independent reactions,
which eventually lead to covalent insertion of the viral
genome into the chromosomal DNA. The first reaction,
3’-processing, is an endonucleolytic cleavage trimming
both the 3’-extremities of the viral DNA, whereas the
second reaction, strand transfer, results in the concomi-
tant insertion of both ends of the viral DNA into a
host-cell chromosome through one-step transesterifica-
tion. IN strand transfer inhibitors (INSTIs) are specific
inhibitors of the strand transfer reaction. The flagship
molecule in this class is raltegravir (RAL), the first
INSTI to have received approval for clinical use for both
treatment-experienced and treatment-naïve patients
[12]. RAL has a rapid and sustained antiretroviral effect
in patients with advanced HIV-1 infection [13,14]. As it
has a different mechanism of action, RAL is also effec-
tive against viruses resistant to other classes of antiretro-
viral drugs [13]. Moreover, although HIV-1 and HIV-2
IN nucleotide sequences are only 40% identical, RAL is
active against wild-type HIV-2, which has a phenotypic
susceptibility to this drug similar to that of HIV-1
[11,15].
However, as for other antiviral drugs, resistance to
RAL emerges rapidly both in vitro and in vivo,t h r o u g h
the selection of mutations within the IN coding region
of the pol gene, greatly reducing the susceptibility of the
virus to the inhibitor. In HIV-1, three main resistance
pathways, involving the residues N155, Q148 and Y143,
have been shown to confer resistance to RAL in vivo.
The virological failure of RAL-based treatment in HIV-1
infection is associated primarily with the initial, inde-
pendent development of the principal N155H and
Q148H/K/R pathways, either alone or together with
other resistance mutations. Secondary resistance muta-
tions, such as G140S, which have little or no direct
effect on drug susceptibility per se, increase phenotypic
resistance or viral fitness [16]. More than 60 mutations
have been shown to be specifically associated with resis-
tance to INSTIs, but biochemical studies have demon-
strated that the mutations affecting residues Y143, Q148
and N155 are sufficient to decrease the susceptibility of
IN to the inhibitor in vitro [16-18]. The third pathway,
involving the Y143R/C mutation, is less frequently
observed and was identified after the N155 and Q148
pathways [17,19,20].
Recent phenotypic studies have established that HIV-2
resistance to RAL may also involve one of the three pri-
mary resistance mutations: N155, Q148 and Y143
[10,21,22]. However, whereas the resistance of HIV-1 IN
to RAL has been confirmed in vitro with IN site-direc-
ted mutants harboring these mutations, no such study
has yet been carried out for the HIV-2 proteins
[ 1 6 , 1 7 , 2 3 ] .W ed e s c r i b eh e r et h ein vitro catalytic activ-
ity and resistance to RAL of HIV-2 recombinant IN iso-
lated from clinical isolates harboring resistance
mutations. By comparing these isolates with IN mutants
generated by single-site mutagenesis, we demonstrate
that G140S/Q148R and N155H are sufficient to confer
resistance to RAL, whereas Y143C mutation is not. We
show also that N155H and Y143C mutations have
antagonistic effects.
Results
Analysis of HIV-2 IN sequences from clinical isolates
before RAL-based treatment
The complete sequence of the HIV-2 IN coding region
from clinical isolates N1 to N3 was determined by
amplification, cloning and sequencing of the IN coding
region of the pol gene from plasma samples obtained at
the start of RAL-based treatment. All three isolates were
HIV-2 group B, as shown by comparisons with the
HIV-2 group B reference sequence EHO, from which
they diverged very little (between 3% and 5% over the
first 293 residues) (Table 1). Substitutions with respect
to the HIV-2 EHO sequence were found in all three
viruses, at nine residues (N17, R34, I133, T180, T215,
R224, N270, M287, V292) and in one or two viruses at
eight other residues (F26, I50, D125, D163, V175, I204,
Q221, I260). These results are consistent with previous
estimates of variation for group B isolates [11]. The
divergence between the three isolates was even weaker,
with only ten residues displaying variation, mostly con-
servative, in one of the three sequences (F26, I50, D125,
D163, V175, T180, I204, T215, Q221, I260), demonstrat-
ing a high degree of conservation of the IN sequence
(Table 1). None of these substitutions affected a residue
previously associated with INSTI resistance in vivo,c o n -
sistent with the absence of prior exposure to INIs. As
expected for group B sequences, the C-terminal domain
was of variable length. Thus, the full length of IN was
301 codons for the virus from patient N1, 299 for the
virus from patient N2 and 293 for the virus from patient
N3. The N1 and N2 sequences had an AQS motif for
codons 293 to 295, consistent with the EHO/B reference
sequence.
We investigated possible effects of sequence and
length variation on IN activity, by producing and
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Page 2 of 10purifying the three proteins according to the protocol
developed for HIV-1 IN, which favors the physiological
Mg
2+-dependent activity of the protein [24]. The three
enzymes, N1, N2 and N3, performed both catalytic
activities efficiently (Figure 1). Differences in specific
activity were observed, through assessments of the
amount of product obtained as a function of enzyme
concentration, but they remained within the range of
variation for recombinant IN preparations, suggesting
that neither divergence at the C-terminal end nor
sequence variation had a significant impact on enzyme
activity in vitro.
The enzymes from clinical isolates N1 to N3 were
obtained from plasma samples collected before treat-
ment with RAL. We confirmed the susceptibility of
these INs to this INSTI, by determining IC50 values in
vitro in dose-response assays carried out in the presence
of various concentrations of inhibitor. RAL efficiently
inhibited the strand transfer activity of the enzyme (Fig-
ure 2A), but had no significant effect on 3’ processing in
vitro at concentrations up to 1 μM (data not shown), as
expected for an INSTI. All three enzymes were suscepti-
ble to RAL (Figure 2B). The clinical isolates of HIV-2
studied were, therefore, susceptible to RAL before treat-
ment initiation. The IC50 values obtained for enzymes
from clinical isolates N1 and N2 were respectively equal
to 23 nM and 30 nM, similar to that obtained for HxB2
HIV-1 IN (IC50 = 28 nM) in these experimental condi-
tions, whereas the IN from N3 had a slightly lower sus-
ceptibility to RAL (IC50 = 48 nM). Thus, sequence
polymorphism may slightly affect IN susceptibility to
RAL.
Identification of mutations associated with RAL resistance
Plasma samples were collected from seven antiretroviral-
experienced RAL-treated HIV-2-infected patients
(patients T1 to T7), at the time of RAL treatment fail-
ure. Complete IN sequences were obtained by amplifica-
tion, cloning and sequencing of the IN coding region.
Patients T1 and T2 were infected with HIV-2 group B
a n dp a t i e n t sT 3t oT 7w e r ei n f e c t e dw i t hH I V - 2g r o u p
A (Table 2). Comparison with the HIV-2 group A refer-
ence sequence ROD showed that all five group A
sequences displayed the following polymorphisms V19I,
R34K, S39T, A41T, T60V, I133V, I180V, I201T, E207D
a tp o s i t i o n st h a tw e r ep r e v i o u s l ys h o w e dt ob es u b j e c t
to variation [11]. All group A viruses harbored a Q148R
resistance mutation, associated with G140S in two cases
(patients T3 and T4) and G140A in two others (patients
T5 and T7; Table 2).
The two B viruses differed from the EHO reference
sequence by identical variations at the following residues:
N17G, R34K, S56A, V72I, I84V, A129V, I133V, E146Q,
T180V, I201L, L213F, T215A, R224Q, D240E and
N270H. One group B sequence harbored the N155H
resistance mutation (patient T1), and another had the
Y143C resistance mutation (patient T2) (Table 2). The
N155H-mutated virus also harbored the E92A and T97A
mutations known to be associated with RAL resistance.
S e v e r a ls u b s t i t u t i o n s ,G 2 7 E ,G 7 0 E ,G 8 2 R ,E 9 2 Q ,a n d
Q124R, were also detected in the Y143C-mutated virus,
including one (E92Q) known to be associated with RAL
resistance. These data confirm that the three main
Table 1 Amino acid variations of HIV-2 IN isolates from INI-naive patients
EHO Reference sequence
Patient Group 17 26 34 50 125 133 163 175 180 204 215 221 224 260 270 287 292
NFRI D I D V T I T Q R I N M V
N1 B G - K V - V - - V V A - Q - H R M
N2 B G - K - - V - I A - N - Q V H R M
N 3 BG Y K V EVN-A-AKQVHRM
n
o
 
 
I
N
substrate
3’ -P product
N1 N2 N3
IN
ST products
12 3 4 56 7 89 10
Figure 1 Study of catalytic properties of INs amplified from
plasma of three INI-naive patients (N1, N2, N3) infected with
HIV-2. Processing activity (bottom panel) and strand transfer activity
(top panel) were assayed as a function of IN concentration. Both
panels represent a unique gel with the top panel corresponding to
a longer exposure. Full assay for catalytic activity was performed as
described in Materials and methods section using a 21-mer (U5A/
U5B) blunt DNA substrate (12,5 nM), with MgCl2 as a cofactor (7.5
mM). Lane 1. No IN. Lanes 2, 5, 8: 100 nM; Lanes 3, 6, 9: 200 nM;
Lanes 4, 7, 10: 300 nM IN. ST: strand transfer; 3’-P: 3’-processing.
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Page 3 of 10mutation patterns giving rise to RAL resistance in HIV-1
are also associated with resistance in HIV-2, as suggested
by the direct sequencing of viral genomes in plasma sam-
ples [15,21].
In vitro enzymatic activity of HIV-2 Ins
Biochemical studies have demonstrated that Q148R,
N155H and Y143C are primary resistance mutations
giving rise to HIV-1 resistance whereas G140S/A and
E92Q are secondary resistance mutations increasing
resistance and viral fitness [16,17]. We determined
whether the roles of these mutations were similar in
HIV-2, by producing and purifying three recombinant
IN sequences corresponding to clinical isolates T1
(N155H; R1), T2 (Y143C; R2) and T3 (G140S/Q148R;
R3). The catalytic activities of these enzymes were
assessed and compared with that of the wild-type sus-
ceptible enzyme from patient N1, used as a control (Fig-
ure 3). Both catalytic activities were affected, to various
extents, in all three enzymes. The N155H-containing
enzyme displayed about 60% the activity of the control
in vitro, within the range of variation for wild-type
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Figure 2 Comparison of in vitro RAL susceptibility of HIV-2 N1-
N3 and HIV-1 HxB2 INs. (A) A representative gel obtained for HIV-
2 N1 IN-mediated strand transfer reaction in the presence of
increasing concentrations of raltegravir. The ST reaction was
performed using a
32P-labeled oligonucleotide mimicking the
preprocessed substrate. Drug concentrations are indicated above
each lane. (B) Susceptibility to RAL of HIV-2 INs. Strand transfer
reaction was carried out for three hours in the presence of 200 nM
IN and increasing concentrations of RAL. Activity is expressed as a %
of control without drug. Experiments were repeated two times.
Table 2 Amino acid substitutions of HIV-2 IN at RAL
failure
Sequence Residue
92 97 143 155
EHO (B) E T Y N
Pat. T1 A A - H
Pat. T2 Q - C -
140 148
ROD (A) G Q
Pat. T3 S R
Pat. T4 S R
Pat.T5 A R
Pat. T6 - R
Pat. T7 A R
0 50 100
Y143C/N155H 
G140S/Q148R
T97A/Y143C
E92Q/Y143C
N155H
Q148R
Y143C
G140S
T97A
E92Q
G140S/Q148R (T3)
 E92Q/Y143C (T2)
E92A/T97A/N155H (T1)
WT (N1)
0 50 100
% 3’-P % ST
A/
B/
Figure 3 In vitro enzymatic activity of HIV-2 INs.3 ’-processing
(3’-P) and strand stranfer (ST) activities of the mutants are
normalized and represented as percentage of activity wild-type B-
type sequence of INI-naïve patient N1 that was taken as a reference
for HIV-2 IN activity. A/INs amplified from HIV-2 infected patients. B/
INs harboring mutations obtained by site-directed mutagenesis in
N1 background.
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Page 4 of 10enzymes. The G140S/Q148R double mutant was more
strongly impaired, displaying only 30% control levels of
activity, and E92Q/Y143C mutant activity was barely
detectable under standard conditions in vitro, indicating
a functional defect.
The mutant enzymes harboring the E92A/T97A/
N155H (T1) and G140S/Q148R (T3) mutations retained
sufficient strand transfer activity for tests of their sus-
ceptibility to RAL, whereas this was not the case for
enzymes with E92Q/Y143C (T2) mutations. The strand
transfer activity of HIV-2 IN was measured in the pre-
sence of various concentrations of RAL (Figure 4).
N155H mutation, in conjunction with secondary substi-
tutions at positions 92 and 97, increased the IC50 by a
factor of about 50, whereas the IC50 was not reached for
the G140S/Q148R double mutant, for concentrations up
to 1 μM. Thus both the N155H- and G140S/Q148R-
containing enzymes were much less susceptible to RAL
in vitro than the wild-type N1 HIV-2 IN, confirming
that these mutations were the cause of viral resistance
to RAL.
Effect of single and double mutations on IN activity in
vitro
We investigated the contribution of each individual
mutation to RAL resistance, by introducing G140S,
Q148R, N155H and Y143C single mutations and the
G140S/Q148R double mutation into the HIV-2 wild-
type IN N1 sequence by site-directed mutagenesis. We
first assessed the impact of these mutations on enzy-
matic activity in vitro, for both the 3’-processing and
strand transfer activities, by comparing the efficiency of
IN activities with that of the wild-type reference N1
enzyme. HIV-2 IN harboring the mutation Q148R had a
much lower level of catalytic activity (<10% wild-type
levels) than the wild-type enzyme (Figure 3). By con-
trast, the N155H mutation had no significant effect on
IN activity. Introduction of the secondary mutation
G140S into the Q148R background resulted in the par-
tial recovery (up to 30% of wild-type levels) of IN cataly-
tic activity, which was strongly impaired by the Q148R
mutation. This result is similar to that obtained for
HIV-1 [16]. The recombinant enzymes harboring the
N155H, Y143C, G140S and G140S/Q148R mutations
were assayed for susceptibility to RAL. The Q148R-con-
taining enzyme only had low levels of activity precluding
precise evaluation of its resistance but preliminary stu-
dies with high protein concentrations suggested that this
enzyme was not susceptible to RAL. The G140S mutant
retained full activity and was as susceptible to RAL as
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Figure 4 In vitro RAL susceptibility of the HIV-2 reference (N1)
and T1 and T3 resistant INs amplified form clinical isolates.
Strand transfer reaction was carried using a 32P-labeled
oligonucleotide mimicking the preprocessed substrate and 200 nM
IN, in the presence of increasing concentrations of RAL at 37°C.
Activity is expressed as a % of control without drug. Experiments
were performed two times.
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Figure 5 In vitro RAL susceptibility of wt and mutated HIV-2
INs. Mutations were introduced in the HIV-2 N1 background by
mutagenesis. (A) Comparison of strand transfer activity in the
presence of RAL of wt (circle), G140S (square) and G140S/Q148R
(triangle) mutants. (B) Comparison of strand transfer activity in the
presence of RAL of wt (circle), N155H (triangle), Y143C (square) and
N155H/Y143C (inverted triangle) HIV-2 INs. Strand transfer reaction
was carried using a 32
P-labeled oligonucleotide mimicking the
preprocessed substrate and 200 nM IN, in the presence of
increasing concentrations of RAL at 37°C. Activity is expressed as a
% of control without drug. Experiments were performed two times.
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Page 5 of 10contrast, introduction of the G140S mutation into the
Q148R background yielded a protein that was highly
resistant to RAL. Thus, the G140S and Q148R muta-
tions play the same role in the resistance of IN to RAL
as in the HIV-1 integrase. Introduction of the N155H
mutation into the wild-type background also resulted in
a high level of resistance (Figure 5B), with a fold-change
with respect to the wild-type enzyme similar to that for
the clinical isolate harboring the E92A/T97A/N155H tri-
ple mutation, which confirmed the identification of
N155H as a primary resistance mutation for HIV-1 IN
[22]. By contrast, introduction of the Y143C mutation
did not lead to significant resistance of the protein in
vitro, suggesting that Y143C is not a primary RAL resis-
tance mutation in HIV-2 IN.
Population sequencing results suggested that resistant
viruses could harbor both the Y143C and 155H muta-
tions. We tested this hypothesis by assaying the double
mutant. However, introduction of the Y143C mutation
into an N155H background significantly decreased resis-
tance levels, by one order of magnitude (IC50 =2 9 0
nM) with respect to the resistant N155H-containing IN
(Figure 5B). The solubility of the Y143C/N155H recom-
binant IN was also lower than that of the other HIV-2
INs, suggesting that proteins carrying both these muta-
tions were unable to adopt an appropriate conformation.
Consistent with this hypothesis, the catalytic activity of
the Y143C/N155H recombinant mutant was strongly
increased by the addition of 10% DMSO (data not
shown), probably because DMSO may help to stabilize
partially folded conformations of proteins [25]. These
observations suggest that the Y143C and N155H muta-
tions are mutually exclusive in a context of natural
selection.
The two group B recombinant enzymes amplified
from clinical isolates T1 and T2 at the time of virologi-
cal failure contained E92A/Q mutations. Such mutations
were previously implicated in the resistance of HIV-1
IN to INSTIs. We investigated the role of the E92 muta-
tion by preparing the E92Q single mutant and the
E92Q/Y143C double mutant in the wild-type N1 back-
ground. Both enzymes were active in vitro,s u g g e s t i n g
that the impairment of the catalytic activity of the T2
IN (E92Q/Y143C) was not directly related to the pre-
sence of these mutations (Figure 6A). The susceptibility
of recombinant INs to RAL was determined by quantify-
ing the inhibition of in vitro strand transfer activity in
the presence of various concentrations of RAL (Figure
6B). Like Y143C, E92Q alone did not confer significant
resistance to RAL in vitro. By contrast, the resistance
level increased when E92Q was introduced into a
Y143C resistant background (IC50 = 370 nM), suggest-
ing that the concomitant presence of the two mutations
was necessary for this significant increase in resistance.
Finally, it has been suggested that the T97A mutation
is involved in resistance to RAL. We tested this hypoth-
esis, by producing a T97A-containing IN. The introduc-
tion of T97A into the Y143C background did not lead
to detectable IN resistance in vitro (Figure 6B), ruling
out a direct role for this mutation in RAL resistance.
Nevertheless, IN harboring the T97A substitution has
higher levels of activity, suggesting that T97A may
increase the fitness of resistant viral mutants.
Discussion
RAL has been reported to be clinically effective against
HIV-2 infection [26,27]. However, HIV-1 and HIV-2 IN
nucleotide sequences are only 40% identical, and their
amino acid sequences are only 65% similar, suggesting
p o s s i b l ed i f f e r e n c e si nt h er e s p o n s eo ft h ee n z y m e st o
inhibitors and in the mechanisms by which resistance
emerges. In this study, we characterized the in vitro
activity of HIV-2 IN produced from the IN coding
region amplified from three plasma samples taken from
RAL naive, HIV-2-infected patients, and from seven
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Figure 6 In vitro RAL susceptibility of wt and mutated HIV-2
INs. Mutations were introduced in the HIV-2 N1 background by
mutagenesis. (A) Representative gel of the strand transfer activity of
recombinant HIV-2 IN mutants in the presence of increasing
concentrations of RAL. (B) Comparison of strand transfer activity in
the presence of RAL of wt (N1) (circle), E92Q (square), Y143C
(triangle), E92Q/Y143C (inverted triangle) and T97A/Y143C
(diamond) mutants. Strand transfer reaction was carried using a
32P-
labeled oligonucleotide mimicking the preprocessed substrate and
200 nM IN, in the presence of increasing concentrations of RAL at
37°C. Activity is expressed as a % of control without drug.
Experiments were performed two times.
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Page 6 of 10others after virological failure following exposure to
RAL.
Clonal analysis of three IN sequences recovered from
the untreated patients identified HIV-2 group B
sequences with different length as already observed for
groups A and B HIV-2 IN [11]. The three IN sequences
studied all displayed the N17G, R34K, I133V, R224Q,
N270H, M287R and V292M variations, with respect to
the EHO group B reference sequence, suggesting that
these variations are prevalent and may even form a con-
sensus in HIV-2 group B circulating strains. This is par-
ticularly likely for the G17, V133 and Q224 residues,
which were also detected in all five group A sequences
amplified. The residues involved in resistance are there-
fore probably less variable than previously thought [11].
The catalytic activities of the three proteins were simi-
lar, and the specific activities of the enzymes in vitro
were similar to that of an HIV-1 IN control, indicating a
lack of impact of C-terminal variation on enzyme activ-
ity. HIV-2 IN-mediated strand transfer was inhibited to
the same extent by RAL in vitro as HIV-1 IN strand
transfer, consistent with the similar phenotypic suscept-
ibilities of HIV-1 and HIV-2 to this class of inhibitor.
This result also indicates that RAL interacts with these
two INs in similar ways. This conclusion is strongly sup-
ported by the complete conservation in HIV-2 of the
HIV-1 IN residues C65, T66, H67, N117, F121, T122,
A128, G149 and K159, which have been implicated in
the interaction with RAL [28].
Whole-population analysis of viral samples recovered
from HIV-2-infected patients who experienced virologi-
cal failure on RAL treatment indicated that the three
main pathways of RAL resistance in HIV-1, involving
mutations of residues Q148, N155 and Y143, may be
also responsible for the resistance of HIV-2 to INSTIs
[26,29,30]. Moreover, a previous clonal analysis found
that E92Q was associated with both the N155H and
Y143C mutations, whereas T97A mutation was asso-
ciated with Y143C [15]. Our clonal analysis based on
seven clinical isolates identified three different patterns,
E92A/T97A/N155H, G140S/Q148R and E92Q/143C,
confirming the probable existence of these three
pathways.
The three recombinant INs obtained by cloning and
expressing these sequences were indeed strongly resis-
tant to RAL in vitro, thereby confirming that the
mutated sequence was responsible for resistance. We
showed, by single-site mutagenesis in a RAL-susceptible
background, that the N155H mutation and the G140S/
Q148H double mutation were sufficient to elicit strong
resistance to RAL in HIV-2 IN in vitro. For the G140S/
Q148H pattern, Q148H caused a major catalytic defect
while conferring a high level of resistance to RAL, the
catalytic defect being rescued in vitro by the secondary
G140S mutation, which did not itself confer resistance.
This result is entirely consistent with our previous
observations for HIV-1 in vitro [16]. The concomitant
selection of the Q148H/R/K and G140S mutations in
both HIV-1 and HIV-2 RAL-resistant viruses is
grounded in the structure of IN, indicating a close inter-
action between these two residues that are conserved in
retroviral IN [31].
A whole-population study suggested a possible asso-
ciation of T97A with both N155H and Y143C mutations
in resistant HIV-2 viruses [21,32]. For the N155H muta-
tion, the level of resistance conferred by single-site
directed mutagenesis was very similar to that of the
enzyme amplified from the E92A/T97A/N155H clinical
isolate, suggesting that the E92A and T97A secondary
mutations provided no additional resistance. This
hypothesis is consistent with the absence of resistance
observed for INs into which T97A and E92Q were
introduced as single mutations. Thus, N155H is the
main, if not only determinant of viral resistance in this
pathway, consistent with the findings of previous pheno-
typic studies of viral replication [22]. Similarly, we
observed no significant effect of T97A in combination
with Y143C, on HIV-2 IN susceptibility to RAL. Never-
theless, limited stimulation of IN activity was detected,
suggesting that this mutation may improve the fitness of
enzymes that would otherwise be catalytically impaired
as previously suggested for HIV-1 IN [33].
Y143C/R has been described as a primary mutation
for HIV-1 resistance to RAL [19]. We previously
demonstrated in vitro that the susceptibility to RAL of
I Nw a ss t r o n g l ya f f e c t e db yt h i ss i n g l em u t a t i o n[ 1 7 ] .
Surprisingly, we observed that, although the Y143C-con-
taining HIV-2 IN was amplified from clinical isolate of a
patient at time of RAL failure, Y143C mutation alone
was not sufficient to confer resistance to IN in vitro, rul-
ing out this mutation as a sole determinant of resistance
in the HIV-2 context. The IN sequence amplified from
the clinical isolate also contained the E92Q mutation.
We therefore studied the impact of this mutation within
the Y143C background. E92Q is considered to be a sec-
ondary mutation within the N155H and Y143C path-
ways for HIV-1 resistance to RAL. Indeed, E92Q confers
resistance to HIV-1 IN in vitro, albeit to a lesser extent
than N155H or Q148R [18]. However, this effect was
not confirmed in the HIV-2 context, because the E92Q
mutation, introduced through single-site directed muta-
genesis, did not significantly increase the resistance of
the HIV-2 mutant IN in vitro. Nonetheless, the Y143C/
E92Q double mutation obtained by mutagenesis of the
wild-type control resulted in resistance in vitro. Thus,
although neither Y143C nor E92Q is sufficient for sig-
nificant resistance to RAL, the presence of both these
substitutions in the same protein leads to resistance
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seem to be required in this pathway to elicit resistance
in HIV-2. A recent structural study suggested that RAL
establishes contact with the side chain of Y143 [31]. We
conclude that, in HIV-2, the loss of this contact is not
sufficient to impair RAL binding to IN. A second modi-
fication to the RAL binding site, which encompasses
E92, is probably required. E92Q has been described as a
primary resistance mutation for another INSTI, elvite-
gravir. Moreover, it was also shown that elvitegravir
remains fully active against Y143 mutant HIV-1 inte-
grase [34]. It would therefore be interesting to deter-
mine whether there are structural similarities between
elvitegravir binding to HIV-1 IN and RAL binding to
HIV-2 IN.
It has been suggested that the emergence of Y143C
during HIV-1 infection may result from a late switch
from the N155H pathway [19]. Our data show that, in
HIV-2 infection, the Y143C mutation counteracts the
resistance conferred by the N155H mutation, probably
precluding the simultaneous selection of both mutations.
Thus, although we did not investigate the effect of E92
mutations on the in vitro resistance of N155H-contain-
ing HIV-2 IN, we suggest that the emergence of E92A/
G/Q secondary mutations, facilitated by the single
nucleotide change required for all substitutions – Et o
A, E to G or E to Q transition – may be involved in the
switch from the N155H to the Y143C pathway in the
HIV-2 context. Under this hypothesis, Y143C-containing
resistant viruses would be expected to be more resistant
to RAL than N155H-containing viruses. This was not
the case here, as the Y143C/E92Q recombinant enzyme
was less resistant than the N155H-containing enzyme.
There may therefore be other, as yet unidentified deter-
minants. Y143C/E92Q-containing INs from clinical iso-
lates also harbored G27E, G70E, G82R and Q124R
variants, which were not found in the HIV-2 group B
RAL-susceptible sequences. Moreover, none of these
residues has previously been identified as a site of major
variation, consistent with selection under RAL pressure
in these isolates. However, these residues have also
never before been associated with the resistance of HIV-
1 or HIV-2 to INSTIs, and their role remains to be
determined [35,36].
Conclusion
In conclusion, this study confirms that HIV-2 resistance
to RAL is due to the N155H, G140S/Q148R or E92Q/
Y143C mutations in the IN coding region. The N155H
and G140S/Q148R mutations make similar contribu-
tions to resistance in both HIV-1 and HIV-2, but Y143C
alone is not sufficient to account for the resistance of
HIV-2 genomes harboring this mutation. For Y143C to
confer resistance in vitro, it must be accompanied by
E92Q, which therefore plays a more important role in
the HIV-2 context than in the HIV-1 context.
Methods
Patients
Plasma samples were collected from three RAL-naive
patients infected with HIV-2, group B (patients N1 to
N3). Two of these patients had previously received anti-
retroviral treatment whereas the third had never been
treated. Plasma samples were also collected from seven
different HIV-2-infected patients, two group B and five
group A, at the time of virological failure on RAL-based
treatment (patients T1 to T7).
Cloning and site-directed mutagenesis
The IN coding sequences from the viruses isolated from
the plasma of HIV-2-infected patients N1 to N3 and T1
to T7 were amplified by PCR and sequenced according
to a previously described procedure [11]. PCR products
corresponding to the entire IN sequence were amplified
again with the following specific primers containing
NdeIa n dBamH I restriction sites at their 5’ ends. Pri-
m e r1 :N 1 ,N 2 ,T 1 ,T 2 ,5 ’-CATATGTTTCTAGAAAA-
GATAGAACCAGC-3’;N 3 ,5 ’-CATATGTTTTTAGAG
AACATAGAACCAGC-3’;T 3 - T 7 ,5 ’-CATATGTTCC
TGGAAAAGATAGAGCCCGC-3’.P r i m e r s2 :N 1 ,5 ’-
GGATCCCTATGCTTCAGGTACTTGACCAG-3’;N 2 ,
5’-GGATCCCAT CCTGGTATCCTCCACGTCGGC-3’;
N3, 5’-GGATCCCTATGCCACCTCTCTAGTCTGC C-
3’;T 1 ,T 2 ,5 ’-GGATCCTTAATTAGACTGTGCCACC
TCTCTAG-3’;T 3 - T 7 ,5 ’-GGATC CCTATGC-
CACCTCTCCATCCTCCCTG -3’. The amplicons were
then ligated into the TA cloning plasmid pGEM-T easy
(Promega, Madison, USA). Single (E92Q, T97A, G140S,
Q148R, Y143C, N155H) and double (G140S/Q148R,
Y143C/N155H, E92Q/Y143C and T97A/Y143C) muta-
tions were introduced into the HIV-2 wild-type N1
sequence by mutagenesis using the QuickChange II site-
directed mutagenesis kit (Agilent Technologies, Santa
Clara, USA) according to the manufacturer instructions.
NdeI-BamHf r a g m e n t sc o v e r i n gt h eI Nc o d i n g
sequence were then inserted into the expression vector
pET-15b.
Expression and purification of recombinant Ins
His-tagged INs were produced in Escherichia coli BL21-
CodonPlus (DE3)-RIPL (Agilent, Santa Clara, USA) and
purified under nondenaturing conditions, as previously
described [24]. Protein production was induced at an
OD600 of 0.6 to 0.8, by adding isopropyl b-D-1-thioga-
lactopyranoside (IPTG) to a concentration of 0.5 mM.
Cultures were incubated for 3 h at 30°C and then centri-
fuged 20 min at 1100 g,4 ° C .C e l l sw e r er e s u s p e n d e di n
buffer A (50 mM Tris-HCl (pH 8), 1 M NaCl, 4 mM b-
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French press. The lysate was centrifuged (30 min at
12,000 g, 4°C), and the supernatant was filtered (pore
size 0.45 μM) and incubated with nickel-nitrilotriacetic
acid agarose beads (Qiagen, Venlo, The Netherlands) for
at least 2 hours at 4°C. The beads were washed with
buffer A and then with buffer A supplemented with 80
mM imidazole. His-tagged proteins were then eluted
from the beads in buffer A supplemented with 1 M imi-
dazole and 50 μM zinc sulfate. They were then dialyzed
overnight against 20 mM Tris-HCl (pH 8), 1 M NaCl, 4
mM b-mercaptoethanol and 10% glycerol. Aliquots of
the purification products were rapidly frozen and stored
at -80°C.
Characterization of IN enzymatic activity in vitro
The activity of wild-type and mutated INs was deter-
mined in vitro, as previously described [24]. Briefly, oli-
gonucleotides (ODN) mimicking the end of the U5 long
terminal repeat of the viral genome were radiolabeled
with T4 polynucleotide kinase (Biolabs, Ipswich, USA)
and [g-
32P] ATP (3,000 Ci/mmol) (Amersham, GE
Healthcare, USA), then purified on a Sephadex G-10
column (GE Healthcare, USA). Double-stranded ODNs
were obtained by mixing equimolar amounts of comple-
m e n t a r ys t r a n d si nt h ep r e s e n c eo f1 0 0m MN a C l .W e
carried out 3’-processing and strand transfer assays at
37°C in a buffer containing 20 mM HEPES (pH 6.8), 1
mM dithiothreitol (DTT), 7.5 mM Mg
2+ and 50 mM
N a C li nt h ep r e s e n c eo fa1 2 . 5n Ms o l u t i o no fU 5 A /
U5B (3’-processing) or U5A/U5B-2 (strand transfer)
double-stranded DNA substrates, respectively. The pro-
ducts were separated by electrophoresis in a 16% acryla-
mide/urea denaturing gel. Gels were analyzed with a
Typhoon TRIO variable mode imager (GE Healthcare,
USA) and quantified with ImageQuant TL software. The
susceptibility of INs to RAL was determined in vitro by
assessing IN activity in the presence of various concen-
trations of RAL. We obtained 50% inhibitory concentra-
tions (IC50) with Prism 5.0 software (GraphPad
Software, San Diego, CA). The HIV-2 ODN substrate
sequences were: UA: 5’-CCTGCTAGGGATTT
TCCTGCCTCGGTTT-3’;U 5 B :5 ’-AAACCGAGGCAG-
GAAAATCCCTAGCAGG-3’; U5B-2: 5’-AAACCGAGG-
CAGGAAAA TCCCTAGCA-3’.
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